BioPharmSignal logoBioPharmSignal

Biotech News

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.2026-06-25 13:46 ESTCompany update

Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle

Open original release

Related news

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Participate in Upcoming Investor Conferences

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

View all latest news

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

OLMAOlema Pharmaceuticals, Inc.2026-06-26 11:33 EST

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

OLMAOlema Pharmaceuticals, Inc.2026-06-26 11:33 EST

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-26 11:33 EST

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-26 11:33 EST

Olema Oncology to Participate in Upcoming Investor Conferences

OLMAOlema Pharmaceuticals, Inc.2026-06-26 11:33 EST

Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States